27446852|t|Duodenal Villous Atrophy in a TTG - Negative Patient Taking Olmesartan: A Case Report and Review of the Literature
27446852|a|Olmesartan, an angiotensin II receptor antagonist used to treat hypertension, is associated with few adverse effects. Here, a case of severe sprue-like enteropathy and acute kidney injury is described in a 68-year-old male taking olmesartan for 3-4 years. He presented to hospital with a five-week history of diarrhea, vomiting, and a 20 lb weight loss. Anti-TTG was negative with a normal IgA. Biopsies of the distal duodenum and duodenal cap revealed marked blunting of the villi with near complete villous atrophy of the biopsies from the bulb. There was an increase in intraepithelial lymphocytes as well as neutrophils in the surface epithelium. The patient's diarrhea improved upon discontinuation of olmesartan and he returned to his previous weight. Repeat endoscopy four months later demonstrated complete resolution of inflammatory change with normal villous architecture. Long-term olmesartan use is associated with severe sprue-like enteropathy. The mechanism of intestinal injury is unknown. Duodenal biopsy results may mimic other enteropathies such as celiac disease. Physicians should consider medications as potential etiologies of enteropathy.
27446852	0	24	Duodenal Villous Atrophy	T033	UMLS:C2677378
27446852	36	44	Negative	T033	UMLS:C0205160
27446852	60	70	Olmesartan	T103	UMLS:C1098320
27446852	74	85	Case Report	T170	UMLS:C0085973
27446852	90	114	Review of the Literature	T170	UMLS:C0282441
27446852	115	125	Olmesartan	T103	UMLS:C1098320
27446852	130	164	angiotensin II receptor antagonist	T103	UMLS:C0521942
27446852	173	178	treat	T058	UMLS:C0087111
27446852	179	191	hypertension	T038	UMLS:C0020538
27446852	216	231	adverse effects	T038	UMLS:C0879626
27446852	256	278	sprue-like enteropathy	T038	UMLS:C0021831
27446852	283	302	acute kidney injury	T037	UMLS:C2609414
27446852	345	355	olmesartan	T103	UMLS:C1098320
27446852	387	395	hospital	T092	UMLS:C0019994
27446852	413	420	history	T033	UMLS:C0262926
27446852	424	432	diarrhea	T033	UMLS:C0011991
27446852	434	442	vomiting	T033	UMLS:C0042963
27446852	456	467	weight loss	T033	UMLS:C1262477
27446852	469	477	Anti-TTG	T033	UMLS:C2673846
27446852	482	490	negative	T033	UMLS:C0205160
27446852	505	508	IgA	T103	UMLS:C0020835
27446852	510	518	Biopsies	T058	UMLS:C0005558
27446852	526	541	distal duodenum	T017	UMLS:C0013303
27446852	546	558	duodenal cap	T017	UMLS:C1284424
27446852	591	596	villi	T017	UMLS:C0227266
27446852	616	631	villous atrophy	T038	UMLS:C0267456
27446852	639	647	biopsies	T058	UMLS:C0005558
27446852	657	661	bulb	T017	UMLS:C0227300
27446852	688	703	intraepithelial	T082	UMLS:C1512942
27446852	704	715	lymphocytes	T017	UMLS:C0024264
27446852	727	738	neutrophils	T017	UMLS:C0027950
27446852	746	764	surface epithelium	T082	UMLS:C1182809
27446852	780	788	diarrhea	T033	UMLS:C0011991
27446852	789	797	improved	T033	UMLS:C0184511
27446852	803	818	discontinuation	T058	UMLS:C0457454
27446852	822	832	olmesartan	T103	UMLS:C1098320
27446852	880	889	endoscopy	T058	UMLS:C0014245
27446852	930	940	resolution	T038	UMLS:C1514893
27446852	976	983	villous	T017	UMLS:C0227266
27446852	1008	1018	olmesartan	T103	UMLS:C1098320
27446852	1049	1071	sprue-like enteropathy	T038	UMLS:C0021831
27446852	1090	1107	intestinal injury	T037	UMLS:C0564863
27446852	1120	1135	Duodenal biopsy	T058	UMLS:C0399805
27446852	1160	1173	enteropathies	T038	UMLS:C0021831
27446852	1182	1196	celiac disease	T038	UMLS:C0007570
27446852	1198	1208	Physicians	T097	UMLS:C0031831
27446852	1225	1236	medications	T058	UMLS:C2081612
27446852	1264	1275	enteropathy	T038	UMLS:C0021831